Legal & privacy

Legal notice

Company information • Investigational status • Forward-looking statements • Privacy

Nature of this website

This website is published for general information about Regentron’s technology, intellectual property, scientific programs, and partnering activities. It is not investment, legal, tax, or medical advice, and it should not be relied upon as the basis for any decision.

Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any security or interest in Regentron FZE or any affiliate, in any jurisdiction. Any such offer would be made only to eligible counterparties through separate definitive documentation, subject to applicable law. Detailed investor and partnering materials are made available to qualified counterparties on request and under confidentiality.

Investigational status

Regentron’s devices, cellular products, tissue-engineered constructs, and delivery systems are investigational. None has received marketing authorization, clearance, or registration from any regulatory authority in any jurisdiction, and none is offered for sale or clinical use.

Nothing on this website should be read as a claim of established safety or efficacy. Where the site refers to historical clinical use, preclinical work, or reported observations, those are described at their actual evidence grade and are expressly not presented as prospective, controlled, or independently verified clinical evidence. Independent replication, source verification, and regulatory classification are workstreams that have not yet been completed.

Historical case material

Certain images and descriptions on this website document historical treatment configurations and follow-up from case materials available to Regentron. They are presented as an early technical proof model, not as Regentron’s primary commercial indication and not as clinical evidence. No patient names, identifiers, or identifying features are published on this website. Any future prospective study would require a separate protocol, ethics or institutional review board approval, site selection, monitoring plan, and regulatory alignment.

Forward-looking statements

This website contains forward-looking statements, including statements about planned studies, milestone gates, regulatory strategy, international filings, manufacturing readiness, partnering intentions, and potential transactions. Forward-looking statements are identifiable by words such as “will,” “plans,” “intends,” “expects,” “designed to,” and “may,” and by descriptions of future activity generally.

Such statements reflect management’s current expectations and are subject to scientific, technical, regulatory, commercial, financing, and legal risks and uncertainties. Actual outcomes may differ materially. In particular, no regulatory approval, clinical result, replication outcome, patent grant or enforceability, freedom-to-operate conclusion, partnership, transaction, price, or timing is assured. Regentron undertakes no obligation to update forward-looking statements except as required by law.

Intellectual property

Patent, utility model, industrial design, and application numbers referenced on this website are provided for information only. Their listing is not a representation as to validity, enforceability, scope, or freedom to operate, and the grant of a right in one jurisdiction confers no protection elsewhere. All granted and pending rights in the estate are registered in the Russian Federation; international protection is a funded workstream and has not been secured. Freedom-to-operate and claim-scope review is ongoing, and no claim of uniqueness is made until that work is complete.

The Regentron name, the Regentron mark, page content, images, and video are the property of Regentron FZE or its licensors and may not be reproduced, distributed, or used commercially without prior written permission. Third-party names and journal titles are the property of their respective owners and are used for identification only.

Privacy statement

Regentron collects as little information as possible through this website.

No cookies. This website sets no cookies and uses no browser storage.
No analytics or tracking. No analytics, advertising, profiling, or third-party tracking scripts are used.
No forms. There are no contact, registration, or subscription forms. The only way to contact us from this site is by email.
Server logs. Our hosting provider may record standard technical request data, such as IP address, timestamp, and user agent, for security and operational purposes.
Email correspondence. If you email us, we process the contact details and content you send in order to respond and to evaluate a potential partnering or investment relationship. We retain that correspondence for as long as necessary for those purposes, do not sell it, and do not use it for marketing without your consent.

Depending on your location, you may have rights of access, rectification, erasure, restriction, objection, or portability in respect of personal data we hold about you. To exercise them, or to ask that we delete your correspondence, write to kv@regentron.com. Regentron FZE is the controller of personal data processed through this website.

External links

This website links to third-party resources, including journal publishers, PubMed, and scientific society pages, so that cited work can be verified independently. Regentron does not control those sites and is not responsible for their content or their privacy practices.

Governing law

This website and this notice are governed by the laws of the United Arab Emirates as applied in the Emirate of Sharjah and Sharjah Publishing City Free Zone, without regard to conflict-of-laws principles. This website is not directed at any person in any jurisdiction where its publication or availability would be contrary to law.

Contact

Questions about this notice, the content of this website, or the handling of your data: kv@regentron.com.

Last updated 3 August 2026.